schliessen

Filtern

 

Bibliotheken

COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series

Introduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic. Method This observational... Full description

Journal Title: Clinical rheumatology 2020-08-27, Vol.39 (11), p.3195-3204
Main Author: Ferri, Clodoveo
Other Authors: Giuggioli, Dilia , Raimondo, Vincenzo , L’Andolina, Massimo , Tavoni, Antonio , Cecchetti, Riccardo , Guiducci, Serena , Ursini, Francesco , Caminiti, Maurizio , Varcasia, Giuseppe , Gigliotti, Pietro , Pellegrini, Roberta , Olivo, Domenico , Colaci, Michele , Murdaca, Giuseppe , Brittelli, Raffaele , Mariano, Giuseppa Pagano , Spinella, Amelia , Bellando-Randone, Silvia , Aiello, Vincenzo , Bilia, Silvia , Giannini, Daiana , Ferrari, Tommaso , Caminiti, Rodolfo , Brusi, Veronica , Meliconi, Riccardo , Fallahi, Poupak , Antonelli, Alessandro
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Cham: Springer International Publishing
ID: ISSN: 0770-3198
Link: https://www.ncbi.nlm.nih.gov/pubmed/32852623
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_gale_infotracacademiconefile_A638628081
title: COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
format: Article
creator:
  • Ferri, Clodoveo
  • Giuggioli, Dilia
  • Raimondo, Vincenzo
  • L’Andolina, Massimo
  • Tavoni, Antonio
  • Cecchetti, Riccardo
  • Guiducci, Serena
  • Ursini, Francesco
  • Caminiti, Maurizio
  • Varcasia, Giuseppe
  • Gigliotti, Pietro
  • Pellegrini, Roberta
  • Olivo, Domenico
  • Colaci, Michele
  • Murdaca, Giuseppe
  • Brittelli, Raffaele
  • Mariano, Giuseppa Pagano
  • Spinella, Amelia
  • Bellando-Randone, Silvia
  • Aiello, Vincenzo
  • Bilia, Silvia
  • Giannini, Daiana
  • Ferrari, Tommaso
  • Caminiti, Rodolfo
  • Brusi, Veronica
  • Meliconi, Riccardo
  • Fallahi, Poupak
  • Antonelli, Alessandro
subjects:
  • Adult
  • Aged
  • Aged, 80 and over
  • Antirheumatic Agents - therapeutic use
  • Arthritis
  • Arthritis, Psoriatic - drug therapy
  • Arthritis, Psoriatic - epidemiology
  • Arthritis, Psoriatic - physiopathology
  • Arthritis, Rheumatoid - drug therapy
  • Arthritis, Rheumatoid - epidemiology
  • Arthritis, Rheumatoid - physiopathology
  • Autoimmune Diseases - drug therapy
  • Autoimmune Diseases - epidemiology
  • Autoimmune Diseases - physiopathology
  • Autoimmune systemic diseases
  • Betacoronavirus
  • Chloroquine
  • Connective tissue diseases
  • Coronavirus Infections - epidemiology
  • Coronavirus Infections - physiopathology
  • Coronaviruses
  • COVID-19
  • Dermatomyositis - drug therapy
  • Dermatomyositis - epidemiology
  • Dermatomyositis - physiopathology
  • Diagnosis
  • Epidemiology
  • Female
  • Glucocorticoids - therapeutic use
  • Humans
  • Immune system
  • Immunosuppressive agents
  • Impact and specific considerations of COVID-19 for clinical rheumatologists
  • Infections
  • Italy - epidemiology
  • Lupus Erythematosus, Systemic - drug therapy
  • Lupus Erythematosus, Systemic - epidemiology
  • Lupus Erythematosus, Systemic - physiopathology
  • Male
  • Medicine
  • Medicine & Public Health
  • Methotrexate
  • Middle Aged
  • Original
  • Original Article
  • Pandemics
  • Patients
  • Pneumonia, Viral - epidemiology
  • Pneumonia, Viral - physiopathology
  • Rheumatic diseases
  • Rheumatic Diseases - drug therapy
  • Rheumatic Diseases - epidemiology
  • Rheumatic Diseases - physiopathology
  • Rheumatology
  • SARS-CoV-2
  • Scleroderma, Systemic - drug therapy
  • Scleroderma, Systemic - epidemiology
  • Scleroderma, Systemic - physiopathology
  • Sjogren's Syndrome - drug therapy
  • Sjogren's Syndrome - epidemiology
  • Sjogren's Syndrome - physiopathology
  • Spondylitis, Ankylosing - drug therapy
  • Spondylitis, Ankylosing - epidemiology
  • Spondylitis, Ankylosing - physiopathology
  • Systemic diseases
  • Undifferentiated Connective Tissue Diseases - drug therapy
  • Undifferentiated Connective Tissue Diseases - epidemiology
  • Undifferentiated Connective Tissue Diseases - physiopathology
ispartof: Clinical rheumatology, 2020-08-27, Vol.39 (11), p.3195-3204
description: Introduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic. Method This observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany), and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1) definite diagnosis of Covid-19 disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2) highly suspected Covid-19 disease: presence of highly suggestive symptoms, in absence of a swab test. Results A significantly higher prevalence of patients with definite diagnosis of Covid-19 disease , or with highly suspected Covid-19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to “Italian general population” ( p  = .030, p  = .001, p  = .000, respectively); and for definite + highly suspected diagnosis of Covid-19 disease, in patients with autoimmune systemic diseases of the three regions ( p  = .000, for all comparisons with the respective regional general population) . Moreover, significantly higher prevalence of definite + highly suspected diagnosis of Covid-19 disease was found either in patients with various “connective tissue diseases” compared to “inflammatory arthritis group” ( p  
language: eng
source:
identifier: ISSN: 0770-3198
fulltext: no_fulltext
issn:
  • 0770-3198
  • 1434-9949
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.7274163
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_gale_infotracacademiconefile_A638628081
sourceformatXML
sourcesystemPC
galeidA638628081
sourcerecordidA638628081
originalsourceidFETCH-LOGICAL-c412t-e3a8c4d1caad70c9b3a902c5504398697714b264e895f2b66fa9bbc590df9ae70
addsrcrecordideNp9UU1v1DAUtBCILgt_gAOyxDnl-SN2zAGpWr5WqtQLcMRynJetqyRe7KRS_z1eUgpckCXbem9mPH5DyEsG5wxAv8llV7oCDhXUQshKPyIbJsvFGGkekw1oDZVgpjkjz3K-AQDeGPaUnAne1FxxsSHfd1ff9u8rZqibOpqucRndHDx1yxzDOC4T0nyXZxxLrQsZXcb8liY8xjTT2FNHB5cOSPezG4Kb6LGwcZozzZgC5ufkSe-GjC_uzy35-vHDl93n6vLq0353cVl5yfhcoXCNlx3zznUavGmFM8B9XYMUplFGayZbriQ2pu55q1TvTNv62kDXG4catuTdqntc2hE7XywkN9hjCqNLdza6YP_tTOHaHuKt1bIGXt7Zktf3Ain-WDDP9iYuaSqebRmUkkoaKQvqfEUd3IA2TH0sYr6s7jSgOGEfSv1CiUbxBhpWCHwl-BRzTtg_WGJgTyHaNURbQrS_QrSnz7z6-zMPlN-pFYBYAbm0pgOmP2b_I_sTjo-oFQ
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid2626464944
display
typearticle
titleCOVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
creatorFerri, Clodoveo ; Giuggioli, Dilia ; Raimondo, Vincenzo ; L’Andolina, Massimo ; Tavoni, Antonio ; Cecchetti, Riccardo ; Guiducci, Serena ; Ursini, Francesco ; Caminiti, Maurizio ; Varcasia, Giuseppe ; Gigliotti, Pietro ; Pellegrini, Roberta ; Olivo, Domenico ; Colaci, Michele ; Murdaca, Giuseppe ; Brittelli, Raffaele ; Mariano, Giuseppa Pagano ; Spinella, Amelia ; Bellando-Randone, Silvia ; Aiello, Vincenzo ; Bilia, Silvia ; Giannini, Daiana ; Ferrari, Tommaso ; Caminiti, Rodolfo ; Brusi, Veronica ; Meliconi, Riccardo ; Fallahi, Poupak ; Antonelli, Alessandro
creatorcontribFerri, Clodoveo ; Giuggioli, Dilia ; Raimondo, Vincenzo ; L’Andolina, Massimo ; Tavoni, Antonio ; Cecchetti, Riccardo ; Guiducci, Serena ; Ursini, Francesco ; Caminiti, Maurizio ; Varcasia, Giuseppe ; Gigliotti, Pietro ; Pellegrini, Roberta ; Olivo, Domenico ; Colaci, Michele ; Murdaca, Giuseppe ; Brittelli, Raffaele ; Mariano, Giuseppa Pagano ; Spinella, Amelia ; Bellando-Randone, Silvia ; Aiello, Vincenzo ; Bilia, Silvia ; Giannini, Daiana ; Ferrari, Tommaso ; Caminiti, Rodolfo ; Brusi, Veronica ; Meliconi, Riccardo ; Fallahi, Poupak ; Antonelli, Alessandro ; COVID-19 & ASD Italian Study Group ; for the COVID-19 & ASD Italian Study Group
descriptionIntroduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic. Method This observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany), and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1) definite diagnosis of Covid-19 disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2) highly suspected Covid-19 disease: presence of highly suggestive symptoms, in absence of a swab test. Results A significantly higher prevalence of patients with definite diagnosis of Covid-19 disease , or with highly suspected Covid-19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to “Italian general population” ( p  = .030, p  = .001, p  = .000, respectively); and for definite + highly suspected diagnosis of Covid-19 disease, in patients with autoimmune systemic diseases of the three regions ( p  = .000, for all comparisons with the respective regional general population) . Moreover, significantly higher prevalence of definite + highly suspected diagnosis of Covid-19 disease was found either in patients with various “connective tissue diseases” compared to “inflammatory arthritis group” ( p  < .000), or in patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs treatments ( p  = .011). Conclusions The finding of a higher prevalence of Covid-19 in patients with autoimmune systemic diseases is particularly important, suggesting the need to develop valuable prevention/management strategies, and stimulates in-depth investigations to verify the possible interactions between Covid-19 infection and impaired immune-system of autoimmune systemic diseases. Key Points • Significantly higher prevalence of Covid-19 is observed in a large series of patients with autoimmune systemic diseases compared to the Italian general population, mainly due to patients’ increased susceptibility to infections and favored by the high exposure to the virus at medical facilities before the restriction measures on individual movement. • The actual prevalence of Covid-19 in autoimmune systemic diseases may be underestimated, possibly due to the wide clinical overlapping between the two conditions, the generally mild Covid-19 disease manifestations, and the limited availability of virological testing. • Patients with “connective tissue diseases” show a significantly higher prevalence of Covid-19, possibly due to deeper immune-system impairment, with respect to “inflammatory arthritis group”. • Covid-19 is more frequent in the subgroup of autoimmune systemic diseases patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs, mainly hydroxyl-chloroquine and methotrexate, which might play some protective role against the most harmful manifestations of Covid-19.
identifier
0ISSN: 0770-3198
1EISSN: 1434-9949
2DOI: 10.1007/s10067-020-05334-7
3PMID: 32852623
languageeng
publisherCham: Springer International Publishing
subjectAdult ; Aged ; Aged, 80 and over ; Antirheumatic Agents - therapeutic use ; Arthritis ; Arthritis, Psoriatic - drug therapy ; Arthritis, Psoriatic - epidemiology ; Arthritis, Psoriatic - physiopathology ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - epidemiology ; Arthritis, Rheumatoid - physiopathology ; Autoimmune Diseases - drug therapy ; Autoimmune Diseases - epidemiology ; Autoimmune Diseases - physiopathology ; Autoimmune systemic diseases ; Betacoronavirus ; Chloroquine ; Connective tissue diseases ; Coronavirus Infections - epidemiology ; Coronavirus Infections - physiopathology ; Coronaviruses ; COVID-19 ; Dermatomyositis - drug therapy ; Dermatomyositis - epidemiology ; Dermatomyositis - physiopathology ; Diagnosis ; Epidemiology ; Female ; Glucocorticoids - therapeutic use ; Humans ; Immune system ; Immunosuppressive agents ; Impact and specific considerations of COVID-19 for clinical rheumatologists ; Infections ; Italy - epidemiology ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Erythematosus, Systemic - epidemiology ; Lupus Erythematosus, Systemic - physiopathology ; Male ; Medicine ; Medicine & Public Health ; Methotrexate ; Middle Aged ; Original ; Original Article ; Pandemics ; Patients ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - physiopathology ; Rheumatic diseases ; Rheumatic Diseases - drug therapy ; Rheumatic Diseases - epidemiology ; Rheumatic Diseases - physiopathology ; Rheumatology ; SARS-CoV-2 ; Scleroderma, Systemic - drug therapy ; Scleroderma, Systemic - epidemiology ; Scleroderma, Systemic - physiopathology ; Sjogren's Syndrome - drug therapy ; Sjogren's Syndrome - epidemiology ; Sjogren's Syndrome - physiopathology ; Spondylitis, Ankylosing - drug therapy ; Spondylitis, Ankylosing - epidemiology ; Spondylitis, Ankylosing - physiopathology ; Systemic diseases ; Undifferentiated Connective Tissue Diseases - drug therapy ; Undifferentiated Connective Tissue Diseases - epidemiology ; Undifferentiated Connective Tissue Diseases - physiopathology
ispartofClinical rheumatology, 2020-08-27, Vol.39 (11), p.3195-3204
rights
0The Author(s) 2020
1COPYRIGHT 2020 Springer
2The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-c412t-e3a8c4d1caad70c9b3a902c5504398697714b264e895f2b66fa9bbc590df9ae70
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32852623$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Ferri, Clodoveo
1Giuggioli, Dilia
2Raimondo, Vincenzo
3L’Andolina, Massimo
4Tavoni, Antonio
5Cecchetti, Riccardo
6Guiducci, Serena
7Ursini, Francesco
8Caminiti, Maurizio
9Varcasia, Giuseppe
10Gigliotti, Pietro
11Pellegrini, Roberta
12Olivo, Domenico
13Colaci, Michele
14Murdaca, Giuseppe
15Brittelli, Raffaele
16Mariano, Giuseppa Pagano
17Spinella, Amelia
18Bellando-Randone, Silvia
19Aiello, Vincenzo
20Bilia, Silvia
21Giannini, Daiana
22Ferrari, Tommaso
23Caminiti, Rodolfo
24Brusi, Veronica
25Meliconi, Riccardo
26Fallahi, Poupak
27Antonelli, Alessandro
28COVID-19 & ASD Italian Study Group
29for the COVID-19 & ASD Italian Study Group
title
0COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
1Clinical rheumatology
addtitle
0Clin Rheumatol
1Clin Rheumatol
descriptionIntroduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic. Method This observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany), and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1) definite diagnosis of Covid-19 disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2) highly suspected Covid-19 disease: presence of highly suggestive symptoms, in absence of a swab test. Results A significantly higher prevalence of patients with definite diagnosis of Covid-19 disease , or with highly suspected Covid-19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to “Italian general population” ( p  = .030, p  = .001, p  = .000, respectively); and for definite + highly suspected diagnosis of Covid-19 disease, in patients with autoimmune systemic diseases of the three regions ( p  = .000, for all comparisons with the respective regional general population) . Moreover, significantly higher prevalence of definite + highly suspected diagnosis of Covid-19 disease was found either in patients with various “connective tissue diseases” compared to “inflammatory arthritis group” ( p  < .000), or in patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs treatments ( p  = .011). Conclusions The finding of a higher prevalence of Covid-19 in patients with autoimmune systemic diseases is particularly important, suggesting the need to develop valuable prevention/management strategies, and stimulates in-depth investigations to verify the possible interactions between Covid-19 infection and impaired immune-system of autoimmune systemic diseases. Key Points • Significantly higher prevalence of Covid-19 is observed in a large series of patients with autoimmune systemic diseases compared to the Italian general population, mainly due to patients’ increased susceptibility to infections and favored by the high exposure to the virus at medical facilities before the restriction measures on individual movement. • The actual prevalence of Covid-19 in autoimmune systemic diseases may be underestimated, possibly due to the wide clinical overlapping between the two conditions, the generally mild Covid-19 disease manifestations, and the limited availability of virological testing. • Patients with “connective tissue diseases” show a significantly higher prevalence of Covid-19, possibly due to deeper immune-system impairment, with respect to “inflammatory arthritis group”. • Covid-19 is more frequent in the subgroup of autoimmune systemic diseases patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs, mainly hydroxyl-chloroquine and methotrexate, which might play some protective role against the most harmful manifestations of Covid-19.
subject
0Adult
1Aged
2Aged, 80 and over
3Antirheumatic Agents - therapeutic use
4Arthritis
5Arthritis, Psoriatic - drug therapy
6Arthritis, Psoriatic - epidemiology
7Arthritis, Psoriatic - physiopathology
8Arthritis, Rheumatoid - drug therapy
9Arthritis, Rheumatoid - epidemiology
10Arthritis, Rheumatoid - physiopathology
11Autoimmune Diseases - drug therapy
12Autoimmune Diseases - epidemiology
13Autoimmune Diseases - physiopathology
14Autoimmune systemic diseases
15Betacoronavirus
16Chloroquine
17Connective tissue diseases
18Coronavirus Infections - epidemiology
19Coronavirus Infections - physiopathology
20Coronaviruses
21COVID-19
22Dermatomyositis - drug therapy
23Dermatomyositis - epidemiology
24Dermatomyositis - physiopathology
25Diagnosis
26Epidemiology
27Female
28Glucocorticoids - therapeutic use
29Humans
30Immune system
31Immunosuppressive agents
32Impact and specific considerations of COVID-19 for clinical rheumatologists
33Infections
34Italy - epidemiology
35Lupus Erythematosus, Systemic - drug therapy
36Lupus Erythematosus, Systemic - epidemiology
37Lupus Erythematosus, Systemic - physiopathology
38Male
39Medicine
40Medicine & Public Health
41Methotrexate
42Middle Aged
43Original
44Original Article
45Pandemics
46Patients
47Pneumonia, Viral - epidemiology
48Pneumonia, Viral - physiopathology
49Rheumatic diseases
50Rheumatic Diseases - drug therapy
51Rheumatic Diseases - epidemiology
52Rheumatic Diseases - physiopathology
53Rheumatology
54SARS-CoV-2
55Scleroderma, Systemic - drug therapy
56Scleroderma, Systemic - epidemiology
57Scleroderma, Systemic - physiopathology
58Sjogren's Syndrome - drug therapy
59Sjogren's Syndrome - epidemiology
60Sjogren's Syndrome - physiopathology
61Spondylitis, Ankylosing - drug therapy
62Spondylitis, Ankylosing - epidemiology
63Spondylitis, Ankylosing - physiopathology
64Systemic diseases
65Undifferentiated Connective Tissue Diseases - drug therapy
66Undifferentiated Connective Tissue Diseases - epidemiology
67Undifferentiated Connective Tissue Diseases - physiopathology
issn
00770-3198
11434-9949
fulltextfalse
rsrctypearticle
creationdate2020
recordtypearticle
recordideNp9UU1v1DAUtBCILgt_gAOyxDnl-SN2zAGpWr5WqtQLcMRynJetqyRe7KRS_z1eUgpckCXbem9mPH5DyEsG5wxAv8llV7oCDhXUQshKPyIbJsvFGGkekw1oDZVgpjkjz3K-AQDeGPaUnAne1FxxsSHfd1ff9u8rZqibOpqucRndHDx1yxzDOC4T0nyXZxxLrQsZXcb8liY8xjTT2FNHB5cOSPezG4Kb6LGwcZozzZgC5ufkSe-GjC_uzy35-vHDl93n6vLq0353cVl5yfhcoXCNlx3zznUavGmFM8B9XYMUplFGayZbriQ2pu55q1TvTNv62kDXG4catuTdqntc2hE7XywkN9hjCqNLdza6YP_tTOHaHuKt1bIGXt7Zktf3Ain-WDDP9iYuaSqebRmUkkoaKQvqfEUd3IA2TH0sYr6s7jSgOGEfSv1CiUbxBhpWCHwl-BRzTtg_WGJgTyHaNURbQrS_QrSnz7z6-zMPlN-pFYBYAbm0pgOmP2b_I_sTjo-oFQ
startdate20200827
enddate20200827
creator
0Ferri, Clodoveo
1Giuggioli, Dilia
2Raimondo, Vincenzo
3L’Andolina, Massimo
4Tavoni, Antonio
5Cecchetti, Riccardo
6Guiducci, Serena
7Ursini, Francesco
8Caminiti, Maurizio
9Varcasia, Giuseppe
10Gigliotti, Pietro
11Pellegrini, Roberta
12Olivo, Domenico
13Colaci, Michele
14Murdaca, Giuseppe
15Brittelli, Raffaele
16Mariano, Giuseppa Pagano
17Spinella, Amelia
18Bellando-Randone, Silvia
19Aiello, Vincenzo
20Bilia, Silvia
21Giannini, Daiana
22Ferrari, Tommaso
23Caminiti, Rodolfo
24Brusi, Veronica
25Meliconi, Riccardo
26Fallahi, Poupak
27Antonelli, Alessandro
general
0Springer International Publishing
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
93V.
107T5
117X7
127XB
1388E
148AO
158FI
168FJ
178FK
18ABUWG
19BENPR
20FYUFA
21GHDGH
22H94
23K9.
24M0S
25M1P
26PQEST
27PQQKQ
28PQUKI
29PRINS
305PM
sort
creationdate20200827
titleCOVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
authorFerri, Clodoveo ; Giuggioli, Dilia ; Raimondo, Vincenzo ; L’Andolina, Massimo ; Tavoni, Antonio ; Cecchetti, Riccardo ; Guiducci, Serena ; Ursini, Francesco ; Caminiti, Maurizio ; Varcasia, Giuseppe ; Gigliotti, Pietro ; Pellegrini, Roberta ; Olivo, Domenico ; Colaci, Michele ; Murdaca, Giuseppe ; Brittelli, Raffaele ; Mariano, Giuseppa Pagano ; Spinella, Amelia ; Bellando-Randone, Silvia ; Aiello, Vincenzo ; Bilia, Silvia ; Giannini, Daiana ; Ferrari, Tommaso ; Caminiti, Rodolfo ; Brusi, Veronica ; Meliconi, Riccardo ; Fallahi, Poupak ; Antonelli, Alessandro
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c412t-e3a8c4d1caad70c9b3a902c5504398697714b264e895f2b66fa9bbc590df9ae70
rsrctypearticles
prefilterarticles
languageeng
creationdate2020
topic
0Adult
1Aged
2Aged, 80 and over
3Antirheumatic Agents - therapeutic use
4Arthritis
5Arthritis, Psoriatic - drug therapy
6Arthritis, Psoriatic - epidemiology
7Arthritis, Psoriatic - physiopathology
8Arthritis, Rheumatoid - drug therapy
9Arthritis, Rheumatoid - epidemiology
10Arthritis, Rheumatoid - physiopathology
11Autoimmune Diseases - drug therapy
12Autoimmune Diseases - epidemiology
13Autoimmune Diseases - physiopathology
14Autoimmune systemic diseases
15Betacoronavirus
16Chloroquine
17Connective tissue diseases
18Coronavirus Infections - epidemiology
19Coronavirus Infections - physiopathology
20Coronaviruses
21COVID-19
22Dermatomyositis - drug therapy
23Dermatomyositis - epidemiology
24Dermatomyositis - physiopathology
25Diagnosis
26Epidemiology
27Female
28Glucocorticoids - therapeutic use
29Humans
30Immune system
31Immunosuppressive agents
32Impact and specific considerations of COVID-19 for clinical rheumatologists
33Infections
34Italy - epidemiology
35Lupus Erythematosus, Systemic - drug therapy
36Lupus Erythematosus, Systemic - epidemiology
37Lupus Erythematosus, Systemic - physiopathology
38Male
39Medicine
40Medicine & Public Health
41Methotrexate
42Middle Aged
43Original
44Original Article
45Pandemics
46Patients
47Pneumonia, Viral - epidemiology
48Pneumonia, Viral - physiopathology
49Rheumatic diseases
50Rheumatic Diseases - drug therapy
51Rheumatic Diseases - epidemiology
52Rheumatic Diseases - physiopathology
53Rheumatology
54SARS-CoV-2
55Scleroderma, Systemic - drug therapy
56Scleroderma, Systemic - epidemiology
57Scleroderma, Systemic - physiopathology
58Sjogren's Syndrome - drug therapy
59Sjogren's Syndrome - epidemiology
60Sjogren's Syndrome - physiopathology
61Spondylitis, Ankylosing - drug therapy
62Spondylitis, Ankylosing - epidemiology
63Spondylitis, Ankylosing - physiopathology
64Systemic diseases
65Undifferentiated Connective Tissue Diseases - drug therapy
66Undifferentiated Connective Tissue Diseases - epidemiology
67Undifferentiated Connective Tissue Diseases - physiopathology
toplevelpeer_reviewed
creatorcontrib
0Ferri, Clodoveo
1Giuggioli, Dilia
2Raimondo, Vincenzo
3L’Andolina, Massimo
4Tavoni, Antonio
5Cecchetti, Riccardo
6Guiducci, Serena
7Ursini, Francesco
8Caminiti, Maurizio
9Varcasia, Giuseppe
10Gigliotti, Pietro
11Pellegrini, Roberta
12Olivo, Domenico
13Colaci, Michele
14Murdaca, Giuseppe
15Brittelli, Raffaele
16Mariano, Giuseppa Pagano
17Spinella, Amelia
18Bellando-Randone, Silvia
19Aiello, Vincenzo
20Bilia, Silvia
21Giannini, Daiana
22Ferrari, Tommaso
23Caminiti, Rodolfo
24Brusi, Veronica
25Meliconi, Riccardo
26Fallahi, Poupak
27Antonelli, Alessandro
28COVID-19 & ASD Italian Study Group
29for the COVID-19 & ASD Italian Study Group
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8ProQuest Central (Corporate)
9Immunology Abstracts
10Health & Medical Collection
11ProQuest Central (purchase pre-March 2016)
12Medical Database (Alumni Edition)
13ProQuest Pharma Collection
14Hospital Premium Collection
15Hospital Premium Collection (Alumni Edition)
16ProQuest Central (Alumni) (purchase pre-March 2016)
17ProQuest Central (Alumni Edition)
18ProQuest Central
19Health Research Premium Collection
20Health Research Premium Collection (Alumni)
21AIDS and Cancer Research Abstracts
22ProQuest Health & Medical Complete (Alumni)
23Health & Medical Collection (Alumni Edition)
24Medical Database
25ProQuest One Academic Eastern Edition
26ProQuest One Academic
27ProQuest One Academic UKI Edition
28ProQuest Central China
29PubMed Central (Full Participant titles)
jtitleClinical rheumatology
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Ferri, Clodoveo
1Giuggioli, Dilia
2Raimondo, Vincenzo
3L’Andolina, Massimo
4Tavoni, Antonio
5Cecchetti, Riccardo
6Guiducci, Serena
7Ursini, Francesco
8Caminiti, Maurizio
9Varcasia, Giuseppe
10Gigliotti, Pietro
11Pellegrini, Roberta
12Olivo, Domenico
13Colaci, Michele
14Murdaca, Giuseppe
15Brittelli, Raffaele
16Mariano, Giuseppa Pagano
17Spinella, Amelia
18Bellando-Randone, Silvia
19Aiello, Vincenzo
20Bilia, Silvia
21Giannini, Daiana
22Ferrari, Tommaso
23Caminiti, Rodolfo
24Brusi, Veronica
25Meliconi, Riccardo
26Fallahi, Poupak
27Antonelli, Alessandro
aucorp
0COVID-19 & ASD Italian Study Group
1for the COVID-19 & ASD Italian Study Group
formatjournal
genrearticle
ristypeJOUR
atitleCOVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
jtitleClinical rheumatology
stitleClin Rheumatol
addtitleClin Rheumatol
date2020-08-27
risdate2020
volume39
issue11
spage3195
epage3204
pages3195-3204
issn0770-3198
eissn1434-9949
abstractIntroduction Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19 pandemic. Method This observational multicenter study included 1641 unselected patients with autoimmune systemic diseases from three Italian geographical areas with different prevalence of Covid-19 [high in north (Emilia Romagna), medium in central (Tuscany), and low in south (Calabria)] by means of telephone 6-week survey. Covid-19 was classified as (1) definite diagnosis of Covid-19 disease: presence of symptomatic Covid-19 infection, confirmed by positive oral/nasopharyngeal swabs; (2) highly suspected Covid-19 disease: presence of highly suggestive symptoms, in absence of a swab test. Results A significantly higher prevalence of patients with definite diagnosis of Covid-19 disease , or with highly suspected Covid-19 disease, or both the conditions together, was observed in the whole autoimmune systemic disease series, compared to “Italian general population” ( p  = .030, p  = .001, p  = .000, respectively); and for definite + highly suspected diagnosis of Covid-19 disease, in patients with autoimmune systemic diseases of the three regions ( p  = .000, for all comparisons with the respective regional general population) . Moreover, significantly higher prevalence of definite + highly suspected diagnosis of Covid-19 disease was found either in patients with various “connective tissue diseases” compared to “inflammatory arthritis group” ( p  < .000), or in patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs treatments ( p  = .011). Conclusions The finding of a higher prevalence of Covid-19 in patients with autoimmune systemic diseases is particularly important, suggesting the need to develop valuable prevention/management strategies, and stimulates in-depth investigations to verify the possible interactions between Covid-19 infection and impaired immune-system of autoimmune systemic diseases. Key Points • Significantly higher prevalence of Covid-19 is observed in a large series of patients with autoimmune systemic diseases compared to the Italian general population, mainly due to patients’ increased susceptibility to infections and favored by the high exposure to the virus at medical facilities before the restriction measures on individual movement. • The actual prevalence of Covid-19 in autoimmune systemic diseases may be underestimated, possibly due to the wide clinical overlapping between the two conditions, the generally mild Covid-19 disease manifestations, and the limited availability of virological testing. • Patients with “connective tissue diseases” show a significantly higher prevalence of Covid-19, possibly due to deeper immune-system impairment, with respect to “inflammatory arthritis group”. • Covid-19 is more frequent in the subgroup of autoimmune systemic diseases patients without ongoing conventional synthetic disease-modifying anti-rheumatic drugs, mainly hydroxyl-chloroquine and methotrexate, which might play some protective role against the most harmful manifestations of Covid-19.
copCham
pubSpringer International Publishing
pmid32852623
doi10.1007/s10067-020-05334-7
oafree_for_read